NIFTY 50 23344.75 ▲ (0.61%)
NIFTY NEXT 50 65106.15 ▲ (0.08%)
NIFTY 100 24048.8 ▲ (0.51%)
NIFTY MIDCAP 100 55106.2 ▲ (0.91%)
NIFTY SMALLCAP 100 17864.65 ▲ (1.09%)
NIFTY SMALLCAP 250 16841.4 ▲ (0.84%)
NIFTY MIDCAP SELECT 12356.5 ▲ (0.87%)
NIFTY TOTAL MARKET 12304.6 ▲ (0.6%)
NIFTY BANK 49350.8 ▲ (1.67%)
SENSEX 77073.44 ▲ (0.59%)
BSE BANKEX 56036.23 ▲ (2.03%)

BIOGEN PHARMACHEM INDUSTRIES : Q4 2024 Financial Quarterly Report

June 21, 2024June 21, 2024| adminadmin| 0 Comments| 6:50 pm
Image is loading
Categories:

Share the post "BIOGEN PHARMACHEM INDUSTRIES : Q4 2024 Financial Quarterly Report"

  • Facebook
  • LinkedIn
  • X
  • Tumblr
  • WhatsApp
  • TelegramTelegram
  • Email

Highlights

  • Sales over the Year and quarter:
  • Income over the Year and quarter: Marginal increase in other income during this quarter, up by 766.67%.
  • Profit over the Year and quarter: Challenges in sustaining profitability for BIOGEN PHARMACHEM INDUSTRIES LIMITED. Profit dropped by -476.14 % Year to Year, BIOGEN PHARMACHEM INDUSTRIES LIMITED’s profitability increased by 1095.16 % in this quarter.
  • EPS over the Year and quarter:

The comprehensive analytics outlining the performance and outlook of BIOGEN PHARMACHEM INDUSTRIES LIMITED”s stock. This analysis encompasses various metrics including stock performance, investor sentiment, market trends, future outlook, risk factors, investment opportunities, long-term strategy, dividend policy, analyst insights, and the overall risk-reward profile. These insights aim to provide investors with a holistic understanding of the company”s stock, enabling informed decision-making and strategic investment planning.

Metrics Previous Year Previous Quarter Current Quarter Quarter to Quarter Difference Year to Year Difference
Sales Rs. -0.01 Cr Rs. 0 Cr Rs. 0 Cr 0 % 0 %
Expenses Rs. 0.19 Cr Rs. 0.03 Cr Rs. 0.04 Cr + 33.33 % -78.95 %
Operating Profit Rs. -0.2 Cr Rs. -0.03 Cr Rs. -0.04 Cr -33.33 % + 80 %
OPM % 2000 % 0 % 0 % 0 % -2000 %
Other Income Rs. -0 Cr Rs. 0.09 Cr Rs. 0.78 Cr + 766.67 % 0 %
Interest Rs. 0 Cr Rs. 0 Cr Rs. 0 Cr 0 % 0 %
Depreciation Rs. 0 Cr Rs. 0 Cr Rs. 0 Cr 0 % 0 %
Profit before tax Rs. -0.2 Cr Rs. 0.06 Cr Rs. 0.74 Cr + 1133.33 % + 470 %
Tax % -0 % 0 % 0 % 0 % 0 %
Net Profit Rs. -0.2 Cr Rs. 0.06 Cr Rs. 0.74 Cr + 1133.33 % + 470 %
EPS in Rs Rs. 0 Rs. 0 Rs. 0.01 0 % 0 %


Today, we’re looking at BIOGEN PHARMACHEM INDUSTRIES LIMITED’s financial performance for the Q4(Mar 2024).Expenses ticked up slightly by 33.33 % quarter-on-quarter, aligning with the annual decline of -78.95 %. Operating profit, while up 80 % compared to last year, faced a quarter-on-quarter dip of -33.33 %, signaling a short-term contraction in margins.
The Operating Profit Margin (OPM) % contradicts this narrative, showing weakness on an annual basis with a decrease of -2000 %, Other income rose by 766.67 % compared to the last quarter, Profit before tax grew annually by 470 % but saw an increase from the preceding quarter by 1133.33 %.
Net profit rose by 470 % year-on-year but experienced a 1133.33 % expansion from the last quarter. In summary, BIOGEN PHARMACHEM INDUSTRIES LIMITED’s annual performance indicates steady growth, although the quarter-on-quarter figures suggest some areas may require strategic attention.

Metrics Previous Year Previous Quarter Current Quarter Quarter to Quarter Difference Year to Year Difference
Sales Rs. -0.01 Cr Rs. 0 Cr Rs. 0 Cr 0 % 0 %
Expenses Rs. 0.19 Cr Rs. 0.03 Cr Rs. 0.04 Cr + 33.33 % -78.95 %
Operating Profit Rs. -0.2 Cr Rs. -0.03 Cr Rs. -0.04 Cr -33.33 % + 80 %
Net Profit Rs. -0.2 Cr Rs. 0.06 Cr Rs. 0.74 Cr + 1133.33 % + 470 %
EPS in Rs Rs. 0 Rs. 0 Rs. 0.01 0 % 0 %


In reviewing BIOGEN PHARMACHEM INDUSTRIES LIMITED’s 2024(Q4) financial snapshot, key trends emerge, shedding light on the company’s performance.Expenses decreased by -78.95 % compared to the previous year, with a 33.33 % increase quarter-on-quarter. Operating Profit surged by 80 % annually, and saw a -33.33 % decrease from the last quarter.
Net Profit showed yearly increase of 470 %, and experienced a 1133.33 % increase from the previous quarter. In essence, while BIOGEN PHARMACHEM INDUSTRIES LIMITED faces strong annual decline indicators, short-term fluctuations suggest the need for agile strategies to navigate market dynamics effectively. That’s all for now in the financial sector.

[my_shortcode1 values=”BIOGEN PHARMACHEM INDUSTRIES “]

Related Post